RankAlpha logo
Back to Rankings

RIGL

RigelD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
+
Peers tracked
10
U.S. public peers
Grade Position
Below peers
vs peer average
RIGL vs peer average
43/100
RIGL vs. peer average (D vs. D)
Grade spread
A 2 · C 1 · D 3 · F 3
Graded peers loaded
Coverage
10 graded
100% of tracked

Peer overview

ANNX is the first available peer comparator.

Annexon is a closer small-cap biotech risk-capital peer for pipeline-value sensitivity, but it lacks Rigel’s current commercial revenue base, so the comparison is mainly about clinical optionality and event volatility.

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerANNXAnnexon
RIGL
Rigel
ANNX
Annexon
Grade
D
C
Momentum
28
37
Value
71
41
Sentiment
44
78
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Defensive
Mixed
Open Side-by-Side ComparisonCompare all

Grade position vs ANNX

RIGL / ANNX
Grade Position
Below peers
RIGL vs. peer average (D vs. D)
43/100
Momentum
28
ANNX
Value
71
RIGL
Sentiment
44
ANNX

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs RIGL
1
ANNX
ANNX
C
60/100
-1
2
AQST
AQST
F
20/100
+1
3
IRWD
IRWD
A
100/100
-3
4
ALT
Altimmune Inc Common
F
20/100
+1
5
CTKB
Cytek Biosciences Inc Common
D
40/100
Even
ANNX is the first peer returned for this comparison set.